C83.16
Mantle cell lymphoma, intrapelvic lymph nodes
Clinical Classification Guidelines
Medical Intelligence & Overview
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma, a cancer that originates in the lymphatic system. When MCL affects the lymph nodes located in the intrapelvic region — the area within the pelvis — it is classified under the ICD-10 code C83.16. This form of lymphoma typically involves the abnormal growth of lymphocytes, a type of white blood cell essential for immune function. Recognizing the features and presentation of this disease helps in understanding the importance of early diagnosis and tailored treatment strategies.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal lymphocyte growth Age-related changes, as it most commonly affects older adults Possible environmental exposures such as pesticides or chemicals (though direct links are still under research) Family history of lymphoma or other hematologic cancers Immune system deficiencies or suppression
Key Symptoms: Swollen lymph nodes in the pelvic area, often painless Unexplained weight loss Persistent fatigue and weakness Fever or night sweats without an obvious infection Abdominal discomfort or swelling due to lymph node enlargement Frequent infections or immune-related complications Possible B symptoms: fever, drenching night sweats, and weight loss
Diagnostic & Treatment
Diagnosis Path: The process of diagnosing mantle cell lymphoma in intrapelvic lymph nodes involves several steps, including laboratory and imaging tests: - Physical Examination: Checking for enlarged lymph nodes, particularly in the pelvic region. - Blood Tests: Evaluating blood cell counts and organ function. - Imaging Studies: Such as CT scans or PET scans to visualize lymph node involvement. - Biopsy: Removing tissue from enlarged lymph nodes for microscopic examination confirms the diagnosis. Specialized tests include immunohistochemistry and genetic studies to identify characteristic markers like cyclin D1 overexpression. - Bone Marrow Biopsy: To assess whether the lymphoma has spread to the bone marrow.
Treatment Protocols: Management of mantle cell lymphoma in intrapelvic lymph nodes typically involves a combination of therapies tailored to the disease stage and patient health: - Chemotherapy: Often the primary treatment to target lymphoma cells. - Immunotherapy: Using monoclonal antibodies such as rituximab to enhance immune response. - Targeted Therapy: Drugs designed to interfere with specific molecules involved in cancer growth. - Radiotherapy: May be used to shrink localized lymph node clusters. - Stem Cell Transplant: In suitable candidates, high-dose chemotherapy followed by stem cell transplantation may be considered. - Clinical Trials: Participation in research studies exploring new treatments. Ongoing monitoring and supportive care are essential components of managing this disease.
Clinical Advice & FAQs
Billing Guidance
Is C83.16 a billable ICD-10 code?
Yes, C83.16 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.16?
Clinical documentation must specify the nature of Mantle cell lymphoma, intrapelvic lymph nodes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference